EUCTR2007-005584-10-GB进行中（未招募）1 期
A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza®) vs. Single Agent MGCD0103 vs. Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia or Intermediate-2 or High-Risk Myelodysplastic Syndrome
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Written informed consent, willingness, and ability to comply with all study procedures;
- •Pathologic confirmation of newly diagnosed (de novo or untreated secondary) AML or newly diagnosed Int-2 or high-risk MDS (IPSS classification) per WHO criteria;
- •Age = 60 years;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2;
- •Total bilirubin = 1.5 x upper limit of normal (ULN) (unless increased due to Gilbert’s disease or hemolysis);
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN;
- •Serum creatinine = 2.0 x ULN; and
- •Use of adequate contraception when appropriate.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects considered fit for intensive chemotherapy who opt to be treated with intensive chemotherapy;
- •Prior transplantation or any prior anticancer therapy (standard or investigational, including chemotherapy, treatment with HDAC inhibitors, or combination HDAC and azacitidine) administered to treat AML or MDS. Prior treatments with agents such as hydroxyurea or corticosteroids used for peripheral count control will be allowed;
- •Known or suspected hypersensitivity to any components of MGCD0103 capsules or azacitidine formulation components (eg, mannitol);
- •Clinical evidence of central nervous system (CNS) involvement by leukemia;
- •In blast transformation of chronic myeloid leukemia (CML);
- •A diagnosis of promyelocytic leukemia;
- •Presence of advanced malignant hepatic tumors;
- •Any condition that will put the subject at undue risk or discomfort as a result of adherence to study procedures (eg , requirement to take MGCD0103 with low pH beverage);
- •Previous or concurrent malignancy except the following: adequately treated basal cell or squamous cell skin cancer; in situ carcinoma of the cervix; or other solid tumor treated curatively and without evidence of recurrence for at least 3 years prior to study entry;
- •Active and uncontrolled clinically significant infection;
- •History of gastrointestinal hemorrhage within the last 3 months;
- •Known positive serology for hepatitis B surface antigen, hepatitis C antibody; or human immunodeficiency virus; or
- •Less than 4 weeks elapsed since any major surgery.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza®) vs. Single Agent MGCD0103 vs. Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia or Intermediate-2 or High-Risk Myelodysplastic Syndromeewly diagnosed Acute Myeloid Leukemia and Intermediate-2, or high-risk Myelodysplastic SyndromeMedDRA version: 9.1Level: LLTClassification code 10000880Term: Acute myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2007-005584-10-SEPharmion Corporation180
进行中（未招募）
不适用
A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza®) vs. Single Agent MGCD0103 vs. Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia or Intermediate-2 or High-Risk Myelodysplastic SyndromeEUCTR2007-005584-10-FRPharmion Corporation180
进行中（未招募）
1 期
A Phase III study of Pembrolizumab compared to Physicians’ choice of Docetaxel, Paclitaxel, or Irinotecan in Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusMedDRA version: 20.0Level: PTClassification code 10030155Term: Oesophageal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Esophageal CarcinomaEUCTR2015-002782-32-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.720
进行中（未招募）
1 期
A Phase III study of Pembrolizumab compared to Physicians’ choice of Docetaxel, Paclitaxel, or Irinotecan in Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusMedDRA version: 21.0Level: PTClassification code 10030155Term: Oesophageal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Esophageal CarcinomaEUCTR2015-002782-32-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.628
进行中（未招募）
1 期
A Phase III study of Pembrolizumab compared to Physicians’ choice of Docetaxel, Paclitaxel, or Irinotecan in Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusMedDRA version: 20.0Level: PTClassification code 10030155Term: Oesophageal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Esophageal CarcinomaEUCTR2015-002782-32-CZMerck Sharp & Dohme Corp.720